Lyon Joseph Douglas's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Dec 3, 2025
- Accession no.
- 0001193125-25-307229
- Filed
- Dec 3, 2025
- Trade date
- Dec 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $397.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyon Joseph DouglasCIK 0001817838 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Common Stock | MOption exerciseAcquired | +5,000 | $13.56 | +$67,800 | 15,277 | Direct | |
| Dec 1, 2025 | Common Stock | SSaleDisposed | −5,000 | $79.53F3 | −$397,650 | 10,277 | Direct | |
| Dec 1, 2025 | Common Stock | AGrant or awardAcquired | +178 | $79.78F5 | +$14,200.84 | 10,455 | Direct | |
| Dec 1, 2025 | Common Stock | AGrant or awardAcquired | +178 | $0.00 | $0 | 10,633 | Direct | |
| Dec 2, 2025 | Common Stock | FTax withholdingDisposed | −110 | $79.78F8 | −$8,775.8 | 10,523 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 11,571 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.73 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F8
The closing price on December 1, 2025 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Accounting & Technology Officer